Navigation Links
Ardea Biosciences Announces Upcoming Corporate Meetings
Date:5/14/2008

very and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment of HIV in a human micro-dose pharmacokinetic study and have selected it as a development candidate. We are also investigating RDEA806 for the treatment of gout. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers for the treatment of inflammatory diseases. We have evaluated our second generation MEK inhibitor, RDEA436, for the treatment of cancer and inflammatory diseases in a human micro-dose pharmacokinetic study, and have selected it as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinica
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
2. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
3. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
4. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
5. Numira Biosciences Names New Board Member
6. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
7. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
8. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
9. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
10. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
11. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 This prestigious award is ... have made outstanding and innovative contributions to the ... of private practice physical therapy by the Private ... , On behalf of Performance Physical Therapy, Michelle ... of Performance accepted the award at the Private ...
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... , , Central and western region facilities ... , , HARRISBURG, Pa., June 4 Over 300 ... healthcare-associated infections (HAIs) this week to the Patient Safety Authority ... western regions of the state will begin reporting by the ...
... and Technologist Symposium at TCT 2009 will examine the ... the management of the cardiovascular patient: ... decisions, Management decisions regarding patients with drug-eluting stents, Leadership, ... own health WHEN: September 21-22, 2009 ...
... available in French . , Montreal, June ... pulmonary disease, is a disease that results in severe breathing ... fourth leading killer worldwide. However the mechanisms responsible for some ... been well understood. Dr.Manuel Cosio from the McGill ...
... Recovery & Reinvestment Act, Electronic Health Records (EHR) implementation and ... Systems Corporation (NYSE: PER ) ( www.perotsystems.com ... "The Impact of The U.S. Stimulus on Healthcare IT," that ... industry. , , To access this video, please click ...
... Alaska Governor Sarah Palin, named "2009 Honoree" by the ... ), will be honored before a sold out crowd of ... on Sunday, June 7(th) at Flowerfields in St. James. , ... Long Island. Independent Group Home Living (IGHL; ...
... Ohio Children,s Hospital Association (OCHA) and its six ... Hospital Medical Center; Dayton Children,s Medical Center; Nationwide ... Cleveland; and Toledo Children,s Hospital - today released ... quality in children,s hospitals. , , OCHA ...
Cached Medicine News:Health News:Over 300 Pennsylvania Nursing Homes in Eastern Pennsylvania Begin Reporting Healthcare-Associated Infections 2Health News:Nurses: Providing angioplasty patient care in and out of the cath lab 2Health News:Investigation finds that cigarette smoking does not affect everyone in same way 2Health News:Perot Systems Releases ARRA Webcast Featuring Leading Analyst Firm 2Health News:Perot Systems Releases ARRA Webcast Featuring Leading Analyst Firm 3Health News:Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30(th) Anniversary Gala During First Visit to Long Island 2Health News:Ohio's Children's Hospitals Release New Results of Collaboration Aimed at Saving Children's Lives 2Health News:Ohio's Children's Hospitals Release New Results of Collaboration Aimed at Saving Children's Lives 3
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Inferior Vena Cava (IVC) Filters - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... reach US$435 million by 2016. The North ... the global value while Europe ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
... distinctive COLOR PURPLE* distinguish SAFESKIN* PURPLE ... sterile clinical procedures when an exceptionally ... designed as an alternative for individuals ... hypersensitivity to natural rubber latex proteins. ...
... Intraoperative Leg Positioner frees the OR staff to ... 2nd assistants to hold the leg, while enabling ... instead of leg positioning. The Siegel MAST Leg ... in any position required for knee surgery and ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Color: ...
... compact design makes this pipette useful ... ammonia in urine, and blood serum ... Deliver" by blowing out the last ... Color: orange Measur range: volume 2.0 ...
Medicine Products: